A novel component of cannabis extract potentiates excitatory synaptic transmission in rat olfactory cortex in vitro

Neuroscience Letters
B J WhalleyA Constanti

Abstract

Cannabis is a potential treatment for epilepsy, although the few human studies supporting this use have proved inconclusive. Previously, we showed that a standardized cannabis extract (SCE), isolated Delta9-tetrahydrocannabinol (Delta9-THC), and even Delta9-THC-free SCE inhibited muscarinic agonist-induced epileptiform bursting in rat olfactory cortical brain slices, acting via CB1 receptors. The present work demonstrates that although Delta9-THC (1 microM) significantly depressed evoked depolarizing postsynaptic potentials (PSPs) in rat olfactory cortex neurones, both SCE and Delta9-THC-free SCE significantly potentiated evoked PSPs (all results were fully reversed by the CB1 receptor antagonist SR141716A, 1 microM); interestingly, the potentiation by Delta9-THC-free SCE was greater than that produced by SCE. On comparing the effects of Delta9-THC-free SCE upon evoked PSPs and artificial PSPs (aPSPs; evoked electrotonically following brief intracellular current injection), PSPs were enhanced, whereas aPSPs were unaffected, suggesting that the effect was not due to changes in background input resistance. Similar recordings made using CB1 receptor-deficient knockout mice (CB1-/-) and wild-type littermate controls revealed cannab...Continue Reading

References

Mar 1, 1980·Journal of Natural Products·C E TurnerE G Boeren
Aug 1, 1981·Journal of Clinical Pharmacology·E A Carlini, J M Cunha
Sep 21, 2000·European Journal of Biochemistry·M D Mark, S Herlitze
Mar 17, 2001·British Journal of Pharmacology·M KathmannE Schlicker
Nov 1, 2001·Archives of General Psychiatry·H G PopeD Yurgelun-Todd
Apr 27, 2002·Science·Rachel I Wilson, Roger A Nicoll
May 31, 2002·Pharmacological Reviews·A C HowlettR G Pertwee
Mar 6, 2003·CNS Drugs·J Ludovic Croxford
Oct 2, 2003·Expert Opinion on Investigational Drugs·Sheila A Doggrell, Suzanne Evans

❮ Previous
Next ❯

Citations

Mar 30, 2010·Psychopharmacology·Jonathan A FarrimondClaire M Williams
Jun 4, 2005·Pharmacology, Biochemistry, and Behavior·Zuzana JustinovaGianluigi Tanda
Mar 18, 2010·Therapeutics and Clinical Risk Management·Paul F Smith
Oct 24, 2014·Analytical and Bioanalytical Chemistry·Oier Aizpurua-OlaizolaAresatz Usobiaga
Sep 20, 2011·Pharmacology & Therapeutics·Andrew J HillGary J Stephens
Jan 8, 2011·Phytotherapy Research : PTR·Jonathan A FarrimondClaire M Williams
Jun 7, 2005·Expert Opinion on Drug Safety·Paul F Smith
Dec 28, 2016·International Journal of Molecular Sciences·Rosaliana LibroOriana Trubiani
Feb 2, 2010·Chemical & Pharmaceutical Bulletin·Justin FischedickRobert Verpoorte

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.